Science Explorer Back to mapMap
Discussion
Company · Loughborough · United Kingdom

Nemaura Pharma (United Kingdom)

nemaura.co.ukROR OpenAlex
Research works
7
▲ 430% vs 2018-21
Citations
39
5.7 per fractional work
Top-10% rate
15.8%
all institutions 10.0%
Open access
45%
world 40%
International
45%
world 18%
Nemaura Pharma (United Kingdom)

Not ranked overall: Nemaura Pharma (United Kingdom) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Nemaura Pharma (United Kingdom) work in?

In all years, 67% of research at Nemaura Pharma (United Kingdom) is in Life Sciences, 20% in Physical Sciences. Its largest fields are Pharmacology, Toxicology and Pharmaceutics (21%), Immunology and Microbiology (19%), Biochemistry, Genetics and Molecular Biology (18%). It does 1.9× the world's share of Life Sciences.

Life Sciences: 5 fractional works · 66.6% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 21.4% of its workPharmaceutical Science: 1 fractional works · 18.0% of its workPharmacology: 0 fractional works · 3.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workImmunology and Microbiology: 1 fractional works · 19.4% of its workImmunology: 1 fractional works · 19.4% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 18.5% of its workMolecular Biology: 1 fractional works · 14.8% of its workPhysiology: 0 fractional works · 2.5% of its workMolecular Medicine: 0 fractional works · 1.2% of its workAgricultural and Biological Sciences: 0 fractional works · 4.8% of its workFood Science: 0 fractional works · 4.8% of its workNeuroscience: 0 fractional works · 2.5% of its workBiological Psychiatry: 0 fractional works · 2.5% of its workPhysical Sciences: 1 fractional works · 19.5% of its workEngineering: 1 fractional works · 12.2% of its workBiomedical Engineering: 0 fractional works · 4.8% of its workAutomotive Engineering: 0 fractional works · 2.5% of its workComputational Mechanics: 0 fractional works · 2.5% of its workMechanical Engineering: 0 fractional works · 2.5% of its workMaterials Science: 0 fractional works · 7.3% of its workBiomaterials: 0 fractional works · 7.3% of its workHealth Sciences: 1 fractional works · 13.9% of its workMedicine: 1 fractional works · 13.9% of its workPulmonary and Respiratory Medicine: 0 fractional works · 4.4% of its workOncology: 0 fractional works · 3.2% of its workPhysiology: 0 fractional works · 2.6% of its workDermatology: 0 fractional works · 1.2% of its workOrthopedics and Sports Medicine: 0 fractional works · 1.2% of its workSurgery: 0 fractional works · 1.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workALL ITS WORKNemaura Pharma(United Kingdom)7fractional works, all years
Life Sciences67%Physical Sciences20%Health Sciences14%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 8 fields, with their numbers
    1. Pharmacology, Toxicology and Pharmaceutics121.4%
    2. Immunology and Microbiology119.4%
    3. Biochemistry, Genetics and Molecular Biology118.5%
    4. Agricultural and Biological Sciences04.8%
    5. Neuroscience02.5%
    1. Engineering112.2%
    2. Materials Science07.3%
    1. Medicine113.9%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

What are the most cited papers from Nemaura Pharma (United Kingdom)?

The most cited paper from Nemaura Pharma (United Kingdom) is "The clinical and translational prospects of microneedle devices, with a focus on insulin therapy for diabetes mellitus as a case study" (Fiona N.C. Smith, Akmal Hidayat Bin Sabri, Matthew Heppel et al., 2022), with 49 citations. Next come "Surface Treatments for Microfluidic Biocompatibility" (15) and "Using Oscillation to Improve the Insertion Depth and Consistency of Hollow Microneedles for Transdermal Insulin Delivery with Mechanistic Insights" (8).

Most cited papers
#PaperReleasedCitations
1 The clinical and translational prospects of microneedle devices, with a focus on insulin therapy for diabetes mellitus as a case study Fiona N.C. Smith, Akmal Hidayat Bin Sabri, Matthew Heppel et al. · International Journal of Pharmaceutics Open access Oct 2022 49
2 Surface Treatments for Microfluidic Biocompatibility Neil James Shirtcliffe, R. Toon, Paul Roach · Methods in molecular biology Book chapter 4 Nov 2012 15
3 Using Oscillation to Improve the Insertion Depth and Consistency of Hollow Microneedles for Transdermal Insulin Delivery with Mechanistic Insights Fiona N.C. Smith, Anna M. Kotowska, Benjamin Fiedler et al. · Molecular Pharmaceutics Open access 3 Dec 2024 8
4 Lyophilised biopolymer-clay hydrogels for drug delivery Farnoosh Kianfar, Nicola M. Dempster, Elsie E. Gaskell et al. · Madridge Journal of Novel Drug Research Open access 30 Jun 2017 6
5 Optimisation of Backing Layer Formulations via Rational Polymer Selection to Improve the Insertion of Dissolving Microneedles Into Skin Fiona C Smith, Benjamin Fiedler, Khaled Elkassas et al. · Molecular Pharmaceutics Open access 9 Jan 2026 5
All 9 most cited papers, with filters and sorting

Which research topics does Nemaura Pharma (United Kingdom) publish most on?

By volume in 2022-now: interferon and immune responses, Galectins and Cancer Biology, Ubiquitin and proteasome pathways and Toxin Mechanisms and Immunotoxins.

interferon and immune re…1interferon and immune responses: 1 fractional worksGalectins and Cancer Bio…0Galectins and Cancer Biology: 0 fractional worksUbiquitin and proteasome…0Ubiquitin and proteasome pathways: 0 fractional worksToxin Mechanisms and Immunotoxins: 0 fractional worksAdvanced Drug Delivery Systems: 0 fractional worksCytokine Signaling Pathw…0Cytokine Signaling Pathways and Interactions: 0 fractional worksAdvancements in Transdermal Drug Delivery: 0 fractional worksPharmacological Effects of Natural Compounds: 0 fractional worksProtein Degradation and Inhibitors: 0 fractional worksPain Mechanisms and Treatments: 0 fractional works
ImmunologyMolecular BiologyPharmaceutical ScienceOncology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 interferon and immune responses Immunology 1 works
  2. 2 Galectins and Cancer Biology Immunology 0 works
  3. 3 Ubiquitin and proteasome pathways Molecular Biology 0 works
  4. 4 Toxin Mechanisms and Immunotoxins Immunology 0 works
  5. 5 Advanced Drug Delivery Systems Pharmaceutical Science 0 works
  6. 6 Cytokine Signaling Pathways and Interactions Oncology 0 works
  7. 7 Advancements in Transdermal Drug Delivery Pharmaceutical Science 0 works
  8. 8 Pharmacological Effects of Natural Compounds Pharmacology 0 works
  9. 9 Protein Degradation and Inhibitors Molecular Biology 0 works
  10. 10 Pain Mechanisms and Treatments Physiology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available45.0%not open55.0%

World: 40% of research is openly available.

with international co-authors45.0%domestic only55.0%

World: 18% is written across borders.

How has Nemaura Pharma (United Kingdom)'s research output changed?

Output in 2022-2025 was 430% higher than in 2018-2021.

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Loughborough

All research institutions in Loughborough

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Nemaura Pharma (United Kingdom). Posts are plain text and can be reported.